Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab [PDF]
Frontiers in Chemistry, 2022 Asparagine deamidation and aspartic acid isomerization in the complementarity determining regions (CDRs) of monoclonal antibodies may alter their affinity to the target antigen. Trastuzumab has two hot spots for deamidation and one position for isomerization in the CDRs.
Baubek Spanov +6 more
openaire +4 more sources
Molecular Imaging, 2014 Human epidermal growth factor receptor (HER)2 imaging with radiolabeled trastuzumab might support HER2-targeted therapy. It is, however, frequently questioned whether HER2 imaging is also possible during trastuzumab treatment as the receptor might be ...
Sietske B.M. Gaykema +8 more
doaj +1 more source
Pharmaceuticals, 2021 This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is
Steven Simoens +2 more
doaj +1 more source
A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells [PDF]
, 2016 Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation
Bown, James +6 more
core +3 more sources
The ErbB2 receptor in gastric cancer. the quick-change artist [PDF]
, 2015 The ErbB family of receptors is providing the oncogenic signals necessary to cells to become transformed. In gastric cancer (GC) the ErbB2 (HER2) expression is associated with a poor prognosis, but addition of ErbB-targeted therapeutics to chemotherapy ...
Alimandi, Maurizio +2 more
core +1 more source
Chemotherapy with or without trastuzumab
Annals of Oncology, 2010 The prognosis of pT1N0M0/stage I breast cancer has generally been considered so favourable that these patients are not routinely offered adjuvant systemic therapy. However, biological heterogeneity within pT1N0M0 dictates diverse outcomes within the subgroup.
Oakman C +5 more
openaire +4 more sources
Trastuzumab: A Picky Partner? [PDF]
Clinical Cancer Research, 2009 Abstract Preclinical and clinical models of HER2-positive breast cancer show that human epidermal growth factor receptor 2 (HER2)-targeted therapy with trastuzumab adds significant benefits and modest risks to conventional cytotoxic therapies.
Clifford A. Hudis, Heather L. McArthur
openaire +3 more sources
Retracted: Trastuzumab induces PUMA‐dependent apoptosis and inhibits tumor growth in gastric cancer
FEBS Open Bio, 2018 Gastric cancer (GC) is one of the most prevalent cancers worldwide. Trastuzumab has been approved for the treatment of metastatic GC, gastroesophageal junction cancer, and breast cancer.
Linghe Luo, Haiyan Liu, Qian Xi
doaj +1 more source
Cell Death and Disease, 2021 Trastuzumab resistance negatively influences the clinical efficacy of the therapy for human epidermal growth factor receptor 2 (HER2) positive gastric cancer (GC), and the underlying mechanisms remain elusive.
Jing Guo +8 more
doaj +1 more source
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]
, 2017 Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal +17 more
core +2 more sources